7Baggers
 innate pharma (nasdaq:ipha) cut to "hold" at leerink partnrs  MarketBeat Wed, 24 Sep 2025 00:17:53 GMT
 innate pharma (nasdaq:ipha) cut to "hold" at leerink partnrs  MarketBeat Tue, 23 Sep 2025 07:00:00 GMT
 innate pharma (nasdaq:ipha) stock rating lowered by hc wainwright  MarketBeat Tue, 23 Sep 2025 05:43:16 GMT
 innate pharma (nasdaq:ipha) stock rating lowered by hc wainwright  MarketBeat Mon, 22 Sep 2025 07:00:00 GMT
 innate pharma fy2025 eps estimate increased by hc wainwright  MarketBeat Mon, 22 Sep 2025 05:19:08 GMT
 leerink partnrs estimates innate pharma q3 earnings  MarketBeat Mon, 22 Sep 2025 05:19:08 GMT
 leerink partnrs downgrades innate pharma (nasdaq:ipha) to hold  MarketBeat Sat, 20 Sep 2025 10:36:11 GMT
 hc wainwright downgrades innate pharma (nasdaq:ipha) to neutral  MarketBeat Fri, 19 Sep 2025 12:20:31 GMT
 IPHA: Leerink Partners Downgrades Innate Pharma, Lowers Price Ta  GuruFocus Thu, 18 Sep 2025 11:44:04 GMT
 Innate Pharma (IPHA) Downgrade: What Investors Need to Know | IP  GuruFocus Thu, 18 Sep 2025 11:14:56 GMT
 innate pharma reports first half 2025 earnings  TipRanks Thu, 18 Sep 2025 09:51:06 GMT
 innate pharma sa reports first half 2025 financial results  TipRanks Thu, 18 Sep 2025 09:51:06 GMT
 Innate Pharma Shares Fall After Downgrades by Leerink, HC Wainwright.  MarketScreener Thu, 18 Sep 2025 07:00:00 GMT
 innate pharma’s strategic shift in earnings call  TipRanks Thu, 18 Sep 2025 00:07:48 GMT
 Innate Pharma Reports First Half 2025 Earnings  TipRanks Wed, 17 Sep 2025 07:00:00 GMT
 Innate Pharma SA Reports First Half 2025 Financial Results  TipRanks Wed, 17 Sep 2025 07:00:00 GMT
 Innate loses 30% of workforce in focus on 'highest-value assets'  Fierce Biotech Wed, 17 Sep 2025 07:00:00 GMT
 Innate Pharma’s Strategic Shift in Earnings Call  TipRanks Wed, 17 Sep 2025 07:00:00 GMT
 Innate Pharma Reports H1 2025 Progress and Strategic Focus  TipRanks Wed, 17 Sep 2025 07:00:00 GMT
 Innate Pharma Releases H1 2025 Financial Report  TipRanks Wed, 17 Sep 2025 07:00:00 GMT
 Innate Pharma Q2 2025 Earnings Call Transcript  MarketBeat Wed, 17 Sep 2025 07:00:00 GMT
 X4 Pharmaceuticals restructures; Cytokinetics targets $650M raise  Endpoints News Wed, 17 Sep 2025 07:00:00 GMT
 innate pharma (otcmkts:iphyf) stock price down 21.3% - here's why  MarketBeat Mon, 15 Sep 2025 09:53:51 GMT
 Innate Pharma to Participate in European Midcap Event  TipRanks Mon, 15 Sep 2025 07:00:00 GMT
 innate pharma (otcmkts:iphyf) trading down 21.3% - here's why  MarketBeat Sat, 13 Sep 2025 04:37:17 GMT
 oklahoma city news - the oklahoman  FinancialContent Wed, 10 Sep 2025 07:00:00 GMT
 published on: 2025-09-06 13:23:59  Newser Sat, 06 Sep 2025 18:23:59 GMT
 published on: 2025-09-04 03:38:19  Newser Thu, 04 Sep 2025 08:38:19 GMT
 innate pharma (nasdaq:ipha) trading 1.7% higher - what's next?  MarketBeat Thu, 04 Sep 2025 07:00:00 GMT
 published on: 2025-09-04 00:58:38  Newser Thu, 04 Sep 2025 05:58:38 GMT
 published on: 2025-09-02 10:31:15  Newser Tue, 02 Sep 2025 15:31:15 GMT
 number of shares and voting rights of innate pharma as of september 1, 2025  Bluefield Daily Telegraph Tue, 02 Sep 2025 07:00:00 GMT
 published on: 2025-08-31 22:08:59  Newser Mon, 01 Sep 2025 03:08:59 GMT
 published on: 2025-08-29 17:30:16  Newser Fri, 29 Aug 2025 22:30:16 GMT
 published on: 2025-08-29 12:22:16  Newser Fri, 29 Aug 2025 17:22:16 GMT
 published on: 2025-08-28 23:38:12  Newser Fri, 29 Aug 2025 04:38:12 GMT
 published on: 2025-08-28 13:21:26  Newser Thu, 28 Aug 2025 18:21:26 GMT
 published on: 2025-08-28 10:01:21  Newser Thu, 28 Aug 2025 15:01:21 GMT
 published on: 2025-08-28 09:45:13  Newser Thu, 28 Aug 2025 14:45:13 GMT
 published on: 2025-08-28 13:28:26  sundaytimes.kr Thu, 28 Aug 2025 04:27:40 GMT
 published on: 2025-08-27 22:04:28  Newser Thu, 28 Aug 2025 03:04:28 GMT

Innate Pharma S.A
(NASDAQ:IPHA) 

IPHA stock logo

Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tu...

Founded: 1999
IPO Price: $5.5 (Oct 17, 2019)
Full Time Employees: 247
CEO: Mondher Mahjoubi  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends